Eisai R&d Management Co., Ltd.

Eisai Company, Limited

Mercian Corporation

Toshimitsu Uenaka

Yoshihiko Kotake

Jun Niijima

Kiyoshi Okamoto

Mitsuo Nagai

Takashi Nakashima

Satoshi Yamamoto

Yuji Yamamoto

Toshio Tsuchida

Junji Matsui

Jing Li

Earl Albone

Masashi Yoshida

Kazuyuki Dobashi

Yoshiharu Mizui

Naoto Kawamura

Tomohiro Sameshima

Masanori Fujita

Takao Yamori

Susumu Takeda

Xin Cheng

Daniel Custar

Naoki Asai

Motoko Matsufuji

Takashi Sakai

Akifumi Okuda

Utpal Majumder

Tomonari Yamada

Koji Norihisa

Keiji Furuuchi

Masao Iwata

Kumiko Kishi

Keisuke Komeda

Takeshi Nagasu

Nozomu Koyanagi

Hiroshi Yoshino

Kentaro Yoshimatsu

Hiroyuki Sugumi

Toshimi Okada

Atsumi Yamaguchi

Kyosuke Kito

Katsuji Nakamura

Jun-ichi Kamata

Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.

Eribulin-based antibody-drug conjugates and methods of use

The present invention provides a method of predicting the antitumor effect of an angiogenesis inhibitor. It is possible to predict the antitumor effect of an angiogenesis inhibitor by evaluating the EGF dependency of a tumor cell for proliferation and/or survival and using the EGF dependency as an indicator. Since the antitumor effect of an angiogenesis inhibitor correlates with the EGF dependency of a tumor cell for proliferation and/or survival, the angiogenesis inhibitors is capable of producing excellent antitumor effect when combined with a substance having EGF inhibitory activity.

Method for assay on the effect of vascularization inhibitor

The present invention provides a method of predicting the antitumor effect of an angiogenesis inhibitor. It is possible to predict the antitumor effect of an angiogenesis inhibitor by evaluating the EOF dependency of a tumor cell for proliferation and/or survival and using the EGF dependency as an indicator. Since the antitumor effect of an angiogenesis inhibitor correlates with the EGF dependency of a tumor cell for proliferation and/or survival, the angiogenesis inhibitors is capable of producing excellent antitumor effect when combined with a substance having EGF inhibitory activity.

The present invention provides a novel bioactive substance having an antitumor activity and a process for producing it, and a medical use thereof. Namely, it provides a 12-membered ring macrolide compound represented by the following formula obtained from the incubation solution ofsp. Mer. 11107 or a variant thereof, a pharmacologically acceptable salt thereof or a hydrate of them, and a process for producing it. 

Bioactive substance

The present invention provides a novel bioactive substance having an antitumor activity and a process for producing it, and a medical use thereof. Namely, it provides a 12-membered ring macrolide compound represented by the following formula obtained from the incubation solution ofsp. Mer. 11107 or a variant thereof, a pharmacologically acceptable salt thereof or a hydrate of them, and a process for producing it

Physiologically active substances

Fused polycyclic heterocycle derivatives

Growing community of inventors

Ibaraki, Japan

Toshimitsu Uenaka